Harrier

Specialisation

Retina and Vitreous.

Full title

Phase III: Two-year, randomised, double-blind, multicentre, two-group trial comparing the efficacy and safety of 6 mg RTH258 compared to aflibercept in subjects with wet age-related macular degeneration.

Promoter

Alcon.

Start date

July 2015.

Researchers

Principal: Dr Anniken Burés